Sandu Pharmaceuticals board meets July 11 on MD demise

What the company told the exchange

Sandu Pharmaceuticals Ltd informed BSE that a meeting of its Board of Directors is scheduled for 11 July 2026. The stated purpose is to place on record the demise of Shri Umesh B. Sandu (DIN: 01132141), the company’s Managing Director, and to record the Board’s appreciation for his contribution to the company.

The disclosure follows the company’s earlier announcement that Shri Umesh B. Sandu, who was also a promoter and Managing Director, passed away on 19 June 2026. The company said it had benefited from his vision and active participation in Board and committee meetings during his tenure.

Board meeting agenda: condolence and appreciation

The board meeting agenda, as indicated in the intimation, is focused on two items: formally noting the demise and recording the Board’s appreciation. Such items are typically handled through board resolutions placed on record as part of statutory and governance processes.

The company’s exchange communication references Shri Umesh Sandu’s involvement across board and committee deliberations. The update also mentions his roles as a member of the Audit Committee and the Stakeholders Relationship Committee.

Timeline of key dates mentioned

The information available in the disclosure creates a clear sequence around the event and the planned board action.

Role held by Umesh B. Sandu

As per the details provided, Umesh B. Sandu served as Managing Director and was an Executive Director. The company described his tenure as marked by active participation in various committee meetings and board meetings.

In the board member snapshot included in the provided material, he is listed as MD and Executive Director, with an indicated tenure of 7.8 years, remuneration of ₹10.28 million, and shareholding of 14.37% (also shown as ₹45.0 million).

Current board leadership and governance set-up

The provided material states that Balram Viswanathan is the current chairman at Sandu Pharmaceuticals. Multiple independent directors are listed, alongside non-executive and promoter-linked directors.

The company’s board and management listings also name Pratika Mhambray as Company Secretary and Compliance Officer, and Vijay Kajarekar as the Chief Financial Officer. A directors’ report excerpt in the supplied text lists these roles as Key Managerial Personnel under Section 203 of the Companies Act, 2013.

Other recent board-level changes mentioned

The broader governance context in the supplied text also includes other personnel updates that were cited as separate company items, including:

• Approval for continuation of Shri Vijay Kajarakar as Chief Financial Officer.
• Resignation of Shubhada Sandu as Non-Executive Non-Independent Director, stated as effective from the closure of business hours on 13 February 2025.
• Appointment of Jayshree Bhasker Sandu as Non-Executive Non-Independent Women Director (also shown with an appointment date of 30 September 2024 in the director listing).

These references, taken together, indicate that Sandu Pharmaceuticals has had multiple board and management updates in the recent period alongside the July 2026 board meeting notice.

Board composition and appointments listed

The director list in the provided text includes the following appointment dates:

• Umesh Bhaskar Sandu, Managing Director, appointed 23 March 1992
• Shashank Bhaskar Sandu, Director, appointed 01 June 2011
• Balram Viswanathan, Director, appointed 14 August 2023
• Ajit Rajaram Kantak, Director, appointed 14 August 2023
• Jayshree Bhasker Sandu, Director, appointed 30 September 2024
• Vijay Kottapalli, Director, CFO, Company Secretary, appointed 12 August 2024

Separately, the material notes that as of 23 December 2025, the company is led by 6 directors, and also provides an “average tenure” figure of 2.7 years and an “average age” of 59.5 years.

Snapshot: remuneration and shareholding data shown

One of the tables in the provided text includes remuneration and ownership for certain board members. Below is a direct snapshot of what is stated.

Market impact: what is and is not stated

The disclosure is a governance update rather than a financial or operational announcement. No revenue, profit, guidance, or operational disruption figures are provided in the text supplied.

What is explicitly stated is the company’s plan to formally record the passing of its Managing Director and acknowledge his contributions through a scheduled board meeting. The supplied directors’ report excerpt also states there were no material changes and commitments affecting the financial position of the company from the end of the financial year until the date of the report.

Why the board meeting matters

For listed companies, recording the demise of a promoter-managing director through board proceedings is an important governance step. It helps ensure statutory records, committee compositions, and key managerial personnel disclosures remain current.

The provided material also places the event in a period that includes multiple board and management updates. Investors typically track such changes for continuity in leadership, clarity on executive responsibilities, and compliance with board and committee requirements.

What to watch next

Based on the stated agenda, the 11 July 2026 meeting is expected to document a condolence resolution and the board’s appreciation. Any subsequent changes in managerial responsibilities or board reconstitution, if decided, would typically be communicated through further exchange filings.

Company contact details provided

The supplied text includes the company’s registered address and contact information:

• Registered Address: Plot No. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Bardez, Goa 403511
• Tel: 0832-6715017 / 0832-6715217
• Email: corp.sec@sandu.in
• Website: http://www.sandu.in

Conclusion

Sandu Pharmaceuticals has scheduled a 11 July 2026 board meeting to place on record the 19 June 2026 demise of its promoter and Managing Director Umesh B. Sandu and to document the Board’s appreciation for his contribution. Further governance updates, if any, would depend on decisions taken and subsequent disclosures to the exchanges.